Engineered ANTI-IL-2 Antibodies
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/IB2021/051267, filed Feb 15, 2021. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,851,485 | Engineered ANTI-IL-2 Antibodies In force · High confidence | Biolojic Design Ltd. | In force | High confidence | ||
| US 12,275,784 | Engineered ANTI-IL-2 Antibodies In force · High confidence | Biolojic Design Ltd. | In force | High confidence | ||
| US 12,312,400 | Engineered ANTI-IL-2 Antibodies In force · High confidence | Biolojic Design Ltd. | In force | High confidence | ||
| Application 19/075,047 | Engineered ANTI-IL-2 Antibodies Pending Not granted | Biolojic Design Ltd. | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Biolojic Design Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.